Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Director Ann L. Macdougall acquired 5,000 shares of Opiant Pharmaceuticals stock in a transaction on Monday, June 4th. The shares were purchased at an average cost of $16.51 per share, with a total value of $82,550.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Opiant Pharmaceuticals opened at $15.20 on Friday, Marketbeat reports. Opiant Pharmaceuticals Inc has a 12 month low of $5.00 and a 12 month high of $51.90. The company has a market cap of $40.20 million, a price-to-earnings ratio of 5.17 and a beta of -0.84.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings data on Tuesday, May 8th. The technology company reported ($3.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($3.39). The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $2.00 million. Opiant Pharmaceuticals had a negative return on equity of 574.62% and a negative net margin of 379.64%. equities research analysts forecast that Opiant Pharmaceuticals Inc will post -5.04 EPS for the current year.
A hedge fund recently bought a new stake in Opiant Pharmaceuticals stock. Acadian Asset Management LLC purchased a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 7,577 shares of the technology company’s stock, valued at approximately $174,000. Acadian Asset Management LLC owned approximately 0.37% of Opiant Pharmaceuticals at the end of the most recent reporting period. 4.34% of the stock is owned by hedge funds and other institutional investors.
Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.